<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:36:25Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8577686" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8577686</identifier>
        <datestamp>2022-06-08</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8577686</article-id>
              <article-id pub-id-type="pmcid">PMC8577686</article-id>
              <article-id pub-id-type="pmc-uid">8577686</article-id>
              <article-id pub-id-type="pmid">34388007</article-id>
              <article-id pub-id-type="pmid">34388007</article-id>
              <article-id pub-id-type="publisher-id">JCO.21.00408</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.21.00408</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>ORIGINAL REPORTS</subject>
                  <subj-group>
                    <subject>Hematologic Malignancy</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Cutter</surname>
                    <given-names>David J.</given-names>
                  </name>
                  <degrees>MD, DPhil</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramroth</surname>
                    <given-names>Johanna</given-names>
                  </name>
                  <degrees>DPhil</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="con1" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Diez</surname>
                    <given-names>Patricia</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Buckle</surname>
                    <given-names>Andy</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ntentas</surname>
                    <given-names>Georgios</given-names>
                  </name>
                  <degrees>DPhil</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Popova</surname>
                    <given-names>Bilyana</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Clifton-Hadley</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                  <xref rid="con2" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoskin</surname>
                    <given-names>Peter J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con3" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Darby</surname>
                    <given-names>Sarah C.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Radford</surname>
                    <given-names>John</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con4" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Illidge</surname>
                    <given-names>Tim</given-names>
                  </name>
                  <degrees>MD, PhD</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con5" ref-type="fn"/>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Nuffield Department of Population Health, University of Oxford, Oxford, <country>United Kingdom</country></aff>
                <aff id="aff2"><label><sup>2</sup></label>Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, <country>United Kingdom</country></aff>
                <aff id="aff3"><label><sup>3</sup></label>National Radiotherapy Trials Quality Assurance Group, Mount Vernon Cancer Centre, Northwood, <country>United Kingdom</country></aff>
                <aff id="aff4"><label><sup>4</sup></label>Department of Medical Physics, Guy's and St Thomas' NHS Foundation Trust, London, <country>United Kingdom</country></aff>
                <aff id="aff5"><label><sup>5</sup></label>Cancer Research UK, UCL Cancer Trials Centre, London, <country>United Kingdom</country></aff>
                <aff id="aff6"><label><sup>6</sup></label>Manchester Academic Health Science Centre, Manchester Cancer Research Centre, University of Manchester, The Christie NHS Foundation Trust, Manchester, <country>United Kingdom</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">David J. Cutter, MD, DPhil, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Roosevelt Dr, Headington, Oxford OX3 7LF, United Kingdom; e-mail: <email>david.cutter@ndph.ox.ac.uk</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>10</day>
                <month>11</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>13</day>
                <month>8</month>
                <year>2021</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>39</volume>
              <issue>32</issue>
              <fpage>3591</fpage>
              <lpage>3601</lpage>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>21</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>30</day>
                  <month>6</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>Licensed under the Creative Commons Attribution 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-39-3591.pdf"/>
              <abstract>
                <sec>
                  <title>PURPOSE</title>
                  <p>The contemporary management of early-stage Hodgkin lymphoma (ES-HL) involves balancing the risk of late adverse effects of radiotherapy against the increased risk of relapse if radiotherapy is omitted. This study provides information on the risk of radiation-related cardiovascular disease to help personalize the delivery of radiotherapy in ES-HL.</p>
                </sec>
                <sec>
                  <title>METHODS</title>
                  <p>We predicted 30-year absolute cardiovascular risk from chemotherapy and involved field radiotherapy in patients who were positron emission tomography (PET)–negative following three cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy within a UK randomized trial of PET-directed therapy for ES-HL. Cardiac and carotid radiation doses and chemotherapy exposure were combined with established dose-response relationships and population-based mortality and incidence rates.</p>
                </sec>
                <sec>
                  <title>RESULTS</title>
                  <p>Average mean heart dose was 4.0 Gy (range 0.1-24.0 Gy) and average bilateral common carotid artery dose was 21.5 Gy (range 0.6-38.1 Gy), based on individualized cardiovascular dosimetry for 144 PET-negative patients receiving involved field radiotherapy. The average predicted 30-year radiation-related absolute excess overall cardiovascular mortality was 0.56% (range 0.01%-6.79%; &lt; 0.5% in 67% of patients and &gt; 1% in 15%), whereas average predicted 30-year excess incidence was 6.24% (range 0.31%-31.09%; &lt; 5% in 58% of patients and &gt; 10% in 24%). For cardiac disease, the average predicted 30-year radiation-related absolute excess mortality was 0.42% (0.79% with mediastinal involvement and 0.05% without) and for stroke, it was 0.14%.</p>
                </sec>
                <sec>
                  <title>CONCLUSION</title>
                  <p>Predicted excess cardiovascular risk is small for most patients, so radiotherapy may provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced radiotherapy techniques to reduce doses or to omit radiotherapy and accept the increased relapse risk. Individual assessment of cardiovascular and other risks before treatment would allow personalized decision making about radiotherapy in ES-HL.</p>
                </sec>
              </abstract>
              <counts>
                <fig-count count="4"/>
                <table-count count="2"/>
                <equation-count count="0"/>
                <ref-count count="44"/>
                <page-count count="0"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Over recent decades, the standard management of early-stage Hodgkin lymphoma (ES-HL) has been combined modality treatment including chemotherapy and radiotherapy. For favorable ES-HL, this is currently two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) chemotherapy and 20 Gy involved field radiotherapy (IFRT), giving excellent 5-year survival (&gt; 90% relapse-free and &gt; 95% overall).<sup><xref rid="b1" ref-type="bibr">1</xref></sup> Attention is now focused on reducing late toxicity. In the past, extended-field radiotherapy and higher radiation doses provided good disease control but incurred substantial risks of second cancers and cardiovascular disease (CVD).<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b3" ref-type="bibr">3</xref></sup> More recently, randomized controlled trials (RCTs) have combined clinical risk factors and positron emission tomography (PET)—a radiologic biomarker of response—to identify patients for whom initial treatment can be less intensive, hopefully reducing long-term toxicity without compromising cure.<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup></p>
              <boxed-text id="B1" position="anchor">
                <sec sec-type="context-box">
                  <title>CONTEXT</title>
                  <p>
                    <list list-type="simple">
                      <list-item>
                        <p>
                          <bold>Key Objective</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>To predict 30-year absolute excess risks of radiation-related cardiovascular disease for positron emission tomography–negative patients given radiotherapy in the UK RAPID trial of early-stage Hodgkin lymphoma using novel methodology that combines individual radiation dosimetry and epidemiologic data.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Knowledge Generated</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>Mean heart dose was &lt; 1 Gy for more than half the patients and &lt; 5 Gy for more than two thirds, whereas mean bilateral common carotid dose was 21 Gy. If radiotherapy were given selectively to the 50% of patients with the lowest predicted risks, then their average predicted 30-year absolute excess risks of radiation-related cardiovascular disease would be 0.11% for mortality and 1.79% for incidence.</p>
                      </list-item>
                      <list-item>
                        <p>
                          <bold>Relevance</bold>
                        </p>
                      </list-item>
                      <list-item>
                        <p>For the majority of positron emission tomography–negative patients in the RAPID trial, the predicted cardiovascular risks are small. These risks should be even lower with the most modern radiotherapy techniques. The decision to give radiotherapy for early-stage Hodgkin lymphoma should be patient-specific, based on individualized risk predictions of dose to critical structures and of all the late effects of these exposures.</p>
                      </list-item>
                    </list>
                  </p>
                </sec>
              </boxed-text>
              <p>The UK National Cancer Research Institute Lymphoma Study Group RAPID trial was an RCT in ES-HL designed to test the omission of radiotherapy following a complete metabolic response on fluorodeoxyglucose-PET scans after three cycles of ABVD. Patients achieving Deauville score<sup><xref rid="b7" ref-type="bibr">7</xref></sup> 1-2 were randomly assigned either to no further treatment (NFT) or to IFRT. Considering all randomly assigned patients, 3-year progression-free survival (PFS) did not differ between the two groups (NFT 90.8% <italic toggle="yes">v</italic> IFRT 94.6%, 3.8% absolute reduction, <italic toggle="yes">P</italic> = .16). However, considering only the patients who received their allocated treatment, the benefit of radiotherapy was significant (NFT 90.8% <italic toggle="yes">v</italic> 97.1%, 6.3% absolute reduction, <italic toggle="yes">P</italic> = .02).<sup><xref rid="b5" ref-type="bibr">5</xref></sup> Further evidence for radiotherapy benefit was reported for the EORTC/LYSA/FIL H10 and GHSG H16 Trials.<sup><xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup> While PFS is appropriate for assessing the efficacy of Hodgkin lymphoma (HL) treatment over 3-5 years, an overall assessment of the effect of radiotherapy needs to take late toxicity into account, balancing a proven improvement in initial disease control versus radiotherapy toxicities that may occur beyond 5-10 years and compromise long-term health and survival.<sup><xref rid="b2" ref-type="bibr">2</xref></sup></p>
              <p>Among HL survivors, cardiac death was, historically, the leading cause of mortality associated with radiotherapy exposure of a single organ.<sup><xref rid="b2" ref-type="bibr">2</xref>,<xref rid="b8" ref-type="bibr">8</xref></sup> While cardiac doses are lower with IFRT than extended-field radiotherapy,<sup><xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b10" ref-type="bibr">10</xref></sup> no detailed description of doses received by individual cardiac substructures with IFRT has been published, nor have any predictions been made of the resulting cardiovascular risks for an RCT cohort.</p>
              <p>The aim of this study is to quantify the cardiovascular radiation doses received by ES-HL patients given IFRT within a recent RCT and to use them to predict the absolute risk of radiation-related CVD. Greater understanding of these risks would improve a personalized approach to the contemporary use of radiotherapy.</p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <sec sec-type="subjects">
                <title>Patients and Treatment</title>
                <p>Six hundred two patients were enrolled into the trial during 2003-2010 (median age, 34 years; range, 16-75 years). Five hundred seventy-one received three cycles of ABVD followed by fluorodeoxyglucose-PET. Among PET-negative individuals (Deauville score 1-2, n = 426), 209 were randomly assigned to IFRT and 183 received it. Among PET-positive individuals (Deauville score 3-5, n = 145), 129 received IFRT (Data Supplement, online only).</p>
                <p>IFRT comprised treating the extent of disease detected by computed tomography (CT) before chemotherapy. There was no intention to treat uninvolved contiguous nodal areas, or entire nodal regions. The recommended field-edge margins were 5 cm up-and-down involved nodal chains with 1.5-2.0 cm lateral margins around the postchemotherapy volume of disease within the mediastinum.<sup><xref rid="b11" ref-type="bibr">11</xref></sup> The dose specified was 30 Gy in 1.8-2.0 Gy fractions, treated in the supine position, by opposed anterior and posterior 5-8 MV beams, both delivered daily.</p>
              </sec>
              <sec>
                <title>Cardiovascular Radiation Dosimetry</title>
                <p>Radiotherapy departments supplied details of the IFRT administered to the National Radiotherapy Trials Quality Assurance team. Where CT planning was used (72%), the original data sets were requested. If the CT did not cover the entire heart, regression was used to estimate the volume missing to calculate heart dose and to estimate doses to cardiac substructures. Where x-ray simulation was used (28%), copies of films were requested and substitute CTs were used to estimate dosimetry. Further details are in the Data Supplement. Treatment data collection and subsequent analysis were approved by the appropriate Research Ethics Committee.</p>
              </sec>
              <sec>
                <title>Prediction of Cardiovascular Risks</title>
                <p>Predictions of 30-year cardiovascular mortality were based on individual radiation doses to the whole heart, left ventricle, heart valves, and common carotid arteries, and the administered anthracycline dose. They were derived using the estimated percentage increases in mortality rate per unit dose obtained from long-term studies of cardiac disease<sup><xref rid="b12" ref-type="bibr">12</xref>-<xref rid="b14" ref-type="bibr">14</xref></sup> and stroke<sup><xref rid="b15" ref-type="bibr">15</xref></sup> following HL treatment, combined with 5-year age- and sex-specific death rates from CVD in the general UK population. Deaths from all causes other than CVD in the general population were competing risks. The 30-year risk of incident CVD was estimated in a similar fashion, using age- and sex-specific first CVD incidence rates from a representative UK cohort<sup><xref rid="b16" ref-type="bibr">16</xref></sup> (details are in the Data Supplement).</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <sec sec-type="subjects">
                <title>Patients Included in the Analysis</title>
                <p>Of the 183 PET-negative patients who received IFRT, data sufficient to complete dosimetry were available for 144 (78.7%, Data Supplement). Of the 129 PET-positive patients who received IFRT, data sufficient to complete dosimetry were available for 103 (79.8%). The baseline characteristics of patients for whom dosimetry was and was not completed were similar (Data Supplement).</p>
              </sec>
              <sec>
                <title>Doses Received by the Heart, Cardiac Substructures, and Carotid Arteries</title>
                <p>For PET-negative patients, the average MHD was 4.0 Gy: 0.3 Gy for those without and 7.8 Gy for those with mediastinal involvement (Table <xref rid="tbl1" ref-type="table">1</xref>). For almost all patients without mediastinal involvement, the MHD was &lt; 1 Gy (72/73, 98.6%), whereas for those with mediastinal involvement, the MHD ranged widely (0.8-24.0 Gy, Table <xref rid="tbl1" ref-type="table">1</xref> and Fig <xref rid="fig1" ref-type="fig">1</xref>A). Considering all PET-negative patients, MHD was &lt; 1 Gy for more than half (76/144, 52.8%) and &lt; 5 Gy for more than two thirds (100/144, 69.4%). The most superior cardiac substructures, such as the pulmonary valve and sinoatrial node, received the highest mean radiation doses (Table <xref rid="tbl1" ref-type="table">1</xref>). The mean radiation dose to the common carotid arteries averaged over 20 Gy but varied widely with peaks for patients receiving unilateral and bilateral neck irradiation (Fig <xref rid="fig1" ref-type="fig">1</xref>B). Dose distributions for PET-positive patients receiving IFRT were similar to those with PET-negative disease (Data Supplement).</p>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1.</label>
                  <caption>
                    <p>Mean Radiation Dose in Gy to the Whole Heart, Cardiac Substructures, and Common Carotid Arteries for All PET-Negative Patients for Whom Dosimetry Was Completed (All), Patients With Mediastinal Involvement (Med+), and Patients Without Mediastinal Involvement (Med−)</p>
                  </caption>
                  <graphic xlink:href="jco-39-3591-g002" position="float"/>
                </table-wrap>
                <fig position="float" id="fig1" fig-type="figure">
                  <label>FIG 1.</label>
                  <caption>
                    <p>Distribution of mean doses in Gy to cardiovascular structures for PET-negative patients receiving radiotherapy and for whom dosimetry was completed (n = 144). (A) Whole heart, showing those with mediastinal involvement (dark blue) and those without (light blue). (B) Common carotid arteries. PET, positron emission tomography.</p>
                  </caption>
                  <graphic xlink:href="jco-39-3591-g003" position="float"/>
                </fig>
              </sec>
              <sec>
                <title>Predicted 30-Year Risks of Cardiovascular Mortality</title>
                <sec>
                  <title>Mortality from heart disease or stroke.</title>
                  <p>The average predicted 30-year cardiovascular mortality risk for PET-negative patients who received IFRT after ABVD was 5.02% (range over individuals 0.30%-19.37%), and comprised 3.52% expected risk from general population rates plus 0.94% absolute excess risk because of anthracycline chemotherapy and a further 0.56% because of IFRT (Fig <xref rid="fig2" ref-type="fig">2</xref>A). The absolute excess risk because of IFRT was dominated by ischemic heart disease (0.36%) and stroke (0.14%; Fig <xref rid="fig2" ref-type="fig">2</xref>B). Considering the radiation-related risk to individual patients, the predicted 30-year absolute excess was &lt; 0.5% in 67% of patients, whereas the median risk (ie, the average of patients ranked 72 and 73 out of 144) was 0.26%. The range across individuals was 0.01%-6.79% (Fig <xref rid="fig3" ref-type="fig">3</xref>A) and the risk was &gt; 1% in 15% of patients. If IFRT were given selectively to the 50% of PET-negative patients with the lowest predicted radiation-related risks, then the average predicted 30-year absolute excess radiation-related cardiovascular risk for these patients would be 0.11% (Fig <xref rid="fig3" ref-type="fig">3</xref>B).</p>
                  <fig position="float" id="fig2" fig-type="figure">
                    <label>FIG 2.</label>
                    <caption>
                      <p>Predicted cardiovascular mortality for PET-negative patients receiving radiotherapy for whom radiation dosimetry was completed (n = 144). (A) Predicted cumulative risks of mortality from heart disease or stroke for the general population, for patients receiving ABVD chemotherapy alone, and for patients receiving ABVD plus IFRT. Cumulative risks allow for the competing risk of noncardiovascular causes of death. (B) Predicted absolute excess risk of mortality from heart disease or stroke for patients receiving ABVD plus IFRT compared with patients receiving ABVD alone, by disease category. (C) Predicted absolute excess risk of mortality from heart disease for patients receiving ABVD plus IFRT compared with patients receiving ABVD alone, by categories of mean whole heart dose in Gy. To achieve comparability across categories, predictions for each category assume all 144 patients received the average radiation dose in that category. (D) Predicted absolute excess risk of mortality from stroke for patients receiving ABVD plus IFRT compared with patients receiving ABVD alone, by categories of mean bilateral common carotid artery dose in Gy. To achieve comparability across categories, predictions for each category assume all 144 patients received the average radiation dose in that category. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; IFRT, involved field radiotherapy; PET, positron emission tomography.</p>
                    </caption>
                    <graphic xlink:href="jco-39-3591-g004" position="float"/>
                  </fig>
                  <fig position="float" id="fig3" fig-type="figure">
                    <label>FIG 3.</label>
                    <caption>
                      <p>Predicted 30-year absolute excess risk of radiation-related heart disease or stroke for PET-negative patients who received radiotherapy and for whom dosimetry was completed (n = 144). Mortality is indicated by orange lines and incidence by black lines. (A) Individual absolute excess risks. Dotted line corresponds to the median excess risk (ie, average of patients ranked 72 and 73 of 144), which was 0.26% for mortality and 3.61% for incidence. (B) Population average absolute excess risks. Dotted line corresponds to population average for irradiated patients if 50% of PET-negative patients with the lowest predicted risks were irradiated. This group of irradiated patients has 0.11% average excess risk for mortality and 1.79% for incidence. PET, positron emission tomography.</p>
                    </caption>
                    <graphic xlink:href="jco-39-3591-g005" position="float"/>
                  </fig>
                </sec>
                <sec>
                  <title>Mortality from heart disease.</title>
                  <p>When the PET-negative patients were subdivided into five categories of MHD, the average predicted 30-year absolute excess risk of radiation-related mortality from heart disease ranged from 0.03% for those receiving &lt; 0.5 Gy MHD to 2.20% for those receiving 10+ Gy (Fig <xref rid="fig2" ref-type="fig">2</xref>C). For individuals, the radiation-related risk ranged from 0.002% to 6.55%. The average was 0.42%; 0.79% for those with mediastinal involvement and 0.05% without. The main determinant of MHD, and hence of cardiac risk, was the inferior border of the radiotherapy field (Data Supplement). Average MHD was higher for females than for males (5.4 <italic toggle="yes">v</italic> 2.7 Gy) because of a higher proportion with mediastinal involvement (59% <italic toggle="yes">v</italic> 41%) and, on average, a lower inferior border to the mediastinal radiation field (median level seventh thoracic vertebra in females <italic toggle="yes">v</italic> sixth in males). Consequently, the predicted <italic toggle="yes">proportional</italic> increase in mortality from heart disease was on average higher for females. However, as men have higher cardiac mortality rates in the general population, the estimated 30-year <italic toggle="yes">absolute</italic> excess mortality risk from treatment-related heart disease (chemotherapy and radiotherapy combined) was actually lower for females (1.2% for females and 1.5% for males, Data Supplement).</p>
                </sec>
                <sec>
                  <title>Mortality from stroke.</title>
                  <p>When the PET-negative patients were grouped into four categories of mean bilateral carotid artery dose, the predicted 30-year average absolute excess radiation-related risk of mortality from stroke varied from 0.05% in those receiving &lt; 10 Gy to 0.24% in those receiving 30+ Gy (Fig <xref rid="fig2" ref-type="fig">2</xref>D). For individual patients, the radiation-related risk ranged from 0.008% to 1.12%, with an average of 0.14%.</p>
                </sec>
              </sec>
              <sec>
                <title>Predicted 30-Year Risks of Incident CVD</title>
                <sec>
                  <title>Incidence of heart disease or stroke.</title>
                  <p>The average predicted 30-year risk of developing CVD for the PET-negative patients receiving IFRT after ABVD was 35.8% (range over individuals 7.7%-86.8%). This comprised 22.9% expected risk from general population rates plus 6.7% absolute excess risk because of anthracycline chemotherapy and a further 6.2% because of IFRT (Fig <xref rid="fig4" ref-type="fig">4</xref>A). The absolute excess risk because of IFRT was dominated by ischemic heart disease (3.28%) and stroke (2.31%; Fig <xref rid="fig4" ref-type="fig">4</xref>B). Considering the radiation-related risk to individual patients, the predicted 30-year absolute excess risk was &lt; 5% in 58% of patients, whereas the median individual risk was 3.61%. The range across individuals was 0.31%-31.09% (Fig <xref rid="fig3" ref-type="fig">3</xref>A) and the risk was &gt; 10% in 24% of patients. If IFRT were given selectively to the 50% of PET-negative patients with the lowest predicted radiation-related cardiovascular risks, then the average predicted 30-year excess absolute radiation-related incidence risk for these patients would be 1.79% (Fig <xref rid="fig3" ref-type="fig">3</xref>B).</p>
                  <fig position="float" id="fig4" fig-type="figure">
                    <label>FIG 4.</label>
                    <caption>
                      <p>Predicted cardiovascular disease incidence for PET-negative patients receiving radiotherapy and for whom radiation dosimetry was completed (n = 144). (A) Predicted cumulative risks of incident heart disease or stroke for the general population, for patients receiving ABVD chemotherapy alone, and for patients receiving ABVD plus IFRT. Cumulative risks allow for the competing risk of noncardiovascular causes of death. (B) Predicted absolute excess risk of incident heart disease or stroke for patients receiving ABVD plus IFRT compared with patients receiving ABVD alone, by disease category. (C) Predicted absolute excess risk of incident heart disease for patients receiving ABVD plus IFRT compared with patients receiving ABVD alone, by categories of mean whole heart dose in Gy. To achieve comparability across categories, predictions for each category assume all 144 patients received the average radiation dose in that category. (D) Predicted absolute excess risk of incident stroke for patients receiving ABVD plus IFRT compared with patients receiving ABVD alone, by categories of mean bilateral common carotid artery dose in Gy. To achieve comparability across categories, predictions for each category assume all 144 patients received the average radiation dose in that category. ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; IFRT, involved field radiotherapy; PET, positron emission tomography.</p>
                    </caption>
                    <graphic xlink:href="jco-39-3591-g006" position="float"/>
                  </fig>
                </sec>
                <sec>
                  <title>Incidence of heart disease.</title>
                  <p>When individuals were grouped into five categories of MHD, the average predicted 30-year absolute excess risk of developing radiation-related heart disease ranged from 0.21% for those receiving &lt; 0.5 Gy MHD to 16.33% for those receiving 10+ Gy (Fig <xref rid="fig4" ref-type="fig">4</xref>C). For individuals, the radiation-related risk ranged from 0.03% to 27.88%. The average was 3.93%; 7.66% for those with mediastinal involvement and 0.31% without.</p>
                </sec>
                <sec>
                  <title>Incidence of stroke.</title>
                  <p>When individuals were grouped into four categories of mean bilateral carotid artery dose, the predicted 30-year absolute excess risk of incident stroke ranged from 0.66% in those receiving &lt; 10 Gy to 3.42% in those receiving ≥ 30 Gy (Fig <xref rid="fig4" ref-type="fig">4</xref>D). For individuals, the radiation-related risk ranged from 0.09% to 5.35%, with an average of 2.31%.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>This study reports the cardiovascular radiation doses received by ES-HL patients treated with IFRT within the RAPID trial and uses them to predict 30-year radiation-related cardiovascular risks for patients who were PET-negative after initial chemotherapy. Because of the varied distribution of disease, the doses received varied widely between individuals and so, therefore, did the predicted radiation-related risks. For 67% of patients, the predicted radiation-related 30-year absolute excess cardiovascular mortality risk was &lt; 0.5% and for 58%, the incidence risk was &lt; 5%. Although these risks are low, they are clinically relevant when considered in the context of an expected 5-year relapse-free survival of &gt; 95% for ES-HL. At the other end of the scale, for 15% of patients, the mortality risk was &gt; 1% and for 24%, the incidence risk was &gt; 10%. For all patients, individualized late toxicity risks should be balanced against the 6%-12% absolute benefit in PFS from consolidation radiotherapy observed in three large RCTs.<sup><xref rid="b4" ref-type="bibr">4</xref>,<xref rid="b5" ref-type="bibr">5</xref>,<xref rid="b6" ref-type="bibr">6</xref></sup></p>
              <p>Our study gives a representative picture of cardiovascular risk from IFRT for all patients in the RAPID trial who were PET-negative after initial chemotherapy. Previous dosimetry studies have concentrated largely on patients with more extensive mediastinal involvement and reported techniques to reduce cardiac exposure.<sup><xref rid="b9" ref-type="bibr">9</xref>,<xref rid="b17" ref-type="bibr">17</xref>-<xref rid="b20" ref-type="bibr">20</xref></sup> In this study, radiotherapy did not include the mediastinum for more than half the patients and we confirm previous findings that the level of mediastinal involvement is a critical determinant of cardiac dose, largely independent of the radiation techniques used.<sup><xref rid="b17" ref-type="bibr">17</xref>,<xref rid="b21" ref-type="bibr">21</xref>,<xref rid="b22" ref-type="bibr">22</xref></sup> With our methods, the minority of patients receiving the highest radiation doses to the heart and carotid arteries have predicted risks of CVD similar to those seen for historical forms of radiotherapy (Table <xref rid="tbl2" ref-type="table">2</xref>) and consistent with results observed from large cohort studies with prolonged follow-up.<sup><xref rid="b15" ref-type="bibr">15</xref>,<xref rid="b23" ref-type="bibr">23</xref></sup> In sharp contrast are the 35% who received only unilateral neck irradiation in the RAPID trial for whom the doses to cardiovascular structures, and consequently the predicted risks, are much lower.</p>
              <table-wrap position="float" id="tbl2">
                <label>TABLE 2.</label>
                <caption>
                  <p>Predicted 30-Year Excess Absolute Risks for Mortality and Incidence of Cardiovascular Diseases for Two Examples of 30 Gy IFRT in Patients of Median Age (34 years) Within the RAPID Trial Cohort, and for an Historical 36 Gy Mantle Field Radiotherapy</p>
                </caption>
                <graphic xlink:href="jco-39-3591-g007" position="float"/>
              </table-wrap>
              <p>Anthracycline-based chemotherapy approximately doubles the risk of cardiac disease from mediastinal irradiation, even in the presence of lower cardiac radiation doses,<sup><xref rid="b24" ref-type="bibr">24</xref>-<xref rid="b26" ref-type="bibr">26</xref></sup> and it increases cardiac mortality risk even in the absence of radiotherapy.<sup><xref rid="b27" ref-type="bibr">27</xref></sup> Anthracycline exposure was therefore included in the models used to predict treatment-related cardiac disease. It is important to recognize that the cardiac risk from chemotherapy in many patients is equal to, or greater than, the risk from radiotherapy. Indeed, we estimate that in the RAPID cohort, the cardiovascular risk from anthracycline exposure exceeded that from radiotherapy in 65% of individuals.</p>
              <p>A strength of this study is the number of individuals (n = 247, 144 PET-negative) for whom dosimetry was completed, which is considerably greater than in the largest previous study reporting cardiac doses from IFRT (n = 41).<sup><xref rid="b9" ref-type="bibr">9</xref></sup> Dosimetry was completed on a high proportion of patients receiving radiotherapy within the trial (79%), and comparison of baseline characteristics suggests that this sample is representative of the entire cohort. The study includes patients from 42 radiotherapy centers across the United Kingdom (87.5% of departments within the trial). It is therefore a representative sample of UK practice at the time.</p>
              <p>There are, however, some limitations to this study. First, not all dosimetry was based on individual anatomy, as substitute CT data sets and data interpolation were used to calculate doses for a minority of patients (28%). This is unlikely to affect the average cardiovascular doses and predicted risks substantially, as demonstrated in a recent study.<sup><xref rid="b28" ref-type="bibr">28</xref></sup> Second, the method used to predict radiation-related CVD has not been prospectively validated, as 20 additional years of follow-up would be required to assess the accuracy of the predictions. Our method is, however, based on the best available epidemiologic evidence regarding the magnitude of the long-term risks of radiation and anthracycline chemotherapy in HL survivors, together with current mortality and incidence rates in the general population. Third, we cannot provide separate risks for patients with pre-existing cardiovascular risk factors such as smoking and diabetes. In the future, adjustments to the model could use individual data on cardiovascular risk factors, but such information was not available for this study. Fourth, we did not attempt to model the possible impact of HL relapse in a small proportion of patients or the cardiotoxicity of subsequent treatments, so it is likely that we are underestimating the net benefit of initial radiotherapy. Finally, although we used the dose metrics from the best epidemiologic evidence currently available<sup><xref rid="b12" ref-type="bibr">12</xref>-<xref rid="b15" ref-type="bibr">15</xref></sup> as the basis for our methods, we recognize the ongoing uncertainty over the radiation dose metric that may best predict the risks of radiation-related cardiac disease and stroke.<sup><xref rid="b29" ref-type="bibr">29</xref>,<xref rid="b30" ref-type="bibr">30</xref></sup></p>
              <p>The challenge of a personalized approach in ES-HL is to balance the risk of late adverse effects from radiotherapy against the omission of radiotherapy, which in turn increases risk of relapse and necessitates further therapy, perhaps including autologous stem-cell transplantation. If, rather than giving radiotherapy to all patients (or to none) regardless of their individual risk of late effects, radiotherapy were given just to patients predicted to be at lower risk of radiation-related CVD, then a substantial proportion of the benefit in terms of recurrence reduction would remain while fewer radiation-related cardiovascular complications would occur. For example, if the 50% of PET-negative patients at lowest risk of cardiovascular complications received radiotherapy, around 50% of the recurrences that would occur by withholding radiotherapy would be prevented, but only one fifth of the excess cardiovascular mortality from irradiating the whole cohort would be incurred (0.11%, Figs <xref rid="fig3" ref-type="fig">3</xref>B, of the total 0.56%, Fig <xref rid="fig2" ref-type="fig">2</xref>A). No individual patient's 30-year excess absolute cardiovascular mortality risk from IFRT would exceed 0.26% (Fig <xref rid="fig3" ref-type="fig">3</xref>A) and the therapeutic ratio of the treatment would be improved. Current efforts to identify which individuals have greatest reduction in relapse risk from upfront radiotherapy (eg, using maximal tumor dimension at diagnosis<sup><xref rid="b31" ref-type="bibr">31</xref></sup>) may also help to identify patients who would benefit most from combined modality treatment.</p>
              <p>It should be noted that developments in radiotherapy techniques since the RAPID trial, including smaller target volumes,<sup><xref rid="b32" ref-type="bibr">32</xref></sup> the use of deep-inspiration breath-hold techniques,<sup><xref rid="b33" ref-type="bibr">33</xref></sup> optimized intensity-modulated radiotherapy,<sup><xref rid="b34" ref-type="bibr">34</xref></sup> and proton beam therapy,<sup><xref rid="b18" ref-type="bibr">18</xref></sup> have reduced irradiated volumes and radiation doses to normal tissues, especially when combined with a 20 Gy prescribed dose for favorable ES-HL.<sup><xref rid="b35" ref-type="bibr">35</xref></sup> Radiation-related CVD is not the only late side effect that may be reduced by the omission of radiotherapy. Risks of second cancers and other radiation-related late toxicities such as xerostomia and hypothyroidism, which would also be reduced by a chemotherapy-only approach, are also likely to be lower with contemporary radiotherapy, but a comprehensive assessment of late toxicities goes beyond the scope of this study. Consideration of all the important toxicities of alternative treatment strategies including the toxicity of treating possible HL relapse would likely suggest that an optimal approach will involve irradiating those ES-HL patients who are at lower risk of RT-related toxicity, rather than a strategy advising radiotherapy for all or none, based only on PET response.</p>
              <p>In conclusion, IFRT for ES-HL as given in RAPID is likely to produce a small increase in the long-term risk of CVD. However, the magnitude of the risk varies widely and, for a majority of patients, the benefit of reduced HL relapse substantially outweighs the risk of CVD. With more modern radiotherapy techniques, the cardiovascular radiation doses achieved<sup><xref rid="b35" ref-type="bibr">35</xref></sup> would result in even lower predicted risks than those seen for the RAPID cohort. As the sites of disease and degree of mediastinal involvement are known at diagnosis, the radiation doses to cardiovascular organs, and hence the risk of radiation-related CVD, can be estimated when the initial treatment strategy is decided. Such an approach could identify high-risk patients who, because of their predicted radiation-related cardiovascular risk, should be considered for treatment with chemotherapy alone as well as for novel radiation techniques, such as deep-inspiration breath-hold techniques and proton beam therapy, that can minimize cardiac exposure.<sup><xref rid="b18" ref-type="bibr">18</xref>,<xref rid="b33" ref-type="bibr">33</xref></sup> As knowledge increases, a personalized assessment including all relevant risks would be helpful in determining the optimal strategy for individual patients.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>ACKNOWLEDGMENT</title>
              <p>The authors thank the investigators, PET centers, and patients from all parts of the United Kingdom for their support.</p>
            </ack>
            <fn-group content-type="presented-at">
              <title>PRIOR PRESENTATION</title>
              <fn fn-type="presented-at">
                <p>Presented at the ISHL-11, Cologne, Germany, October 27-29, 2018.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn fn-type="supported-by">
                <p>Supported by Cancer Research UK grant (C8225/A21133) and by the British Heart Foundation Centre for Research Excellence, Oxford (grants RE/08/04 and RE/13/1/30181). T.I. and P.H. are supported by the Manchester NIHR Biomedical Research Centre. Funding for the RAPID trial (ClinicalTrials.gov identifier, <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT00943423" ext-link-type="uri">NCT00943423</ext-link>) was provided by the Leukaemia and Lymphoma Research (now Blood Cancer UK), the Lymphoma Research Trust, Teenage Cancer Trust, and the UK Department of Health. The RAPID trial was run by the Cancer Research UK and University College London Cancer Trials Centre.</p>
              </fn>
            </fn-group>
            <fn-group>
              <fn id="afn1" fn-type="equal">
                <label>*</label>
                <p>D.J.C. and J. Ramroth contributed equally to this work as first authors. J. Radford and T.I. contributed equally to this work as last authors.</p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>All data requests relating to the RAPID trial should be submitted for consideration to the trial sponsor via the Chief Investigator (<email>john.radford@manchester.ac.uk</email>). All data requests relating to the dosimetric and risk prediction analysis should be submitted to the corresponding author (<email>david.cutter@ndph.ox.ac.uk</email>). All information necessary to reproduce the calculation of cardiovascular risks is provided or referenced in the Data Supplement.</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> David J. Cutter, Patricia Diez, John Radford, Tim Illidge</p>
              <p><bold>Administrative support:</bold> Bilyana Popova, Laura Clifton-Hadley</p>
              <p><bold>Provision of study materials or patients:</bold> Patricia Diez, Bilyana Popova, John Radford</p>
              <p><bold>Collection and assembly of data:</bold> David J. Cutter, Johanna Ramroth, Patricia Diez, Andy Buckle, Bilyana Popova</p>
              <p><bold>Data analysis and interpretation:</bold> David J. Cutter, Johanna Ramroth, Georgios Ntentas, Peter J. Hoskin, Sarah C. Darby, Tim Illidge</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="COI-statement">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="http://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
                <fn-group>
                  <fn id="con1" fn-type="other">
                    <p>
                      <bold>Johanna Ramroth</bold>
                    </p>
                    <p><bold>Employment:</bold> Gilead Sciences (I)</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Gilead Sciences</p>
                  </fn>
                  <fn id="con2" fn-type="financial-disclosure">
                    <p>
                      <bold>Laura Clifton-Hadley</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Various pharmaceutical companies</p>
                  </fn>
                  <fn id="con3" fn-type="financial-disclosure">
                    <p>
                      <bold>Peter J. Hoskin</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta</p>
                  </fn>
                  <fn id="con4" fn-type="financial-disclosure">
                    <p>
                      <bold>John Radford</bold>
                    </p>
                    <p><bold>Stock and Other Ownership Interests:</bold> AstraZeneca, ADC Therapeutics</p>
                    <p><bold>Honoraria:</bold> Takeda, ADC Therapeutics</p>
                    <p><bold>Consulting or Advisory Role:</bold> Takeda, Seattle Genetics, Novartis</p>
                    <p><bold>Speakers' Bureau:</bold> Takeda, Seattle Genetics, Novartis</p>
                    <p><bold>Research Funding:</bold> Takeda</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Takeda, ADC Therapeutics</p>
                  </fn>
                  <fn id="con5" fn-type="COI-statement">
                    <p>
                      <bold>Tim Illidge</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Takeda, Nordic Nanovector</p>
                    <p><bold>Speakers' Bureau:</bold> Takeda, Bristol Myers Squibb, Roche</p>
                    <p><bold>Research Funding:</bold> AstraZeneca/MedImmune, MSD Oncology</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Roche</p>
                    <p>No other potential conflicts of interest were reported.</p>
                  </fn>
                </fn-group>
              </sec>
            </sec>
            <notes>
              <fn-group>
                <fn fn-type="other">
                  <p>
                    <bold>Johanna Ramroth</bold>
                  </p>
                  <p><bold>Employment:</bold> Gilead Sciences (I)</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Gilead Sciences</p>
                </fn>
                <fn fn-type="financial-disclosure">
                  <p>
                    <bold>Laura Clifton-Hadley</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Various pharmaceutical companies</p>
                </fn>
                <fn fn-type="financial-disclosure">
                  <p>
                    <bold>Peter J. Hoskin</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Varian Medical Systems, Astellas Pharma, Bayer, Roche, Pfizer, Elekta</p>
                </fn>
                <fn fn-type="financial-disclosure">
                  <p>
                    <bold>John Radford</bold>
                  </p>
                  <p><bold>Stock and Other Ownership Interests:</bold> AstraZeneca, ADC Therapeutics</p>
                  <p><bold>Honoraria:</bold> Takeda, ADC Therapeutics</p>
                  <p><bold>Consulting or Advisory Role:</bold> Takeda, Seattle Genetics, Novartis</p>
                  <p><bold>Speakers' Bureau:</bold> Takeda, Seattle Genetics, Novartis</p>
                  <p><bold>Research Funding:</bold> Takeda</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Takeda, ADC Therapeutics</p>
                </fn>
                <fn fn-type="COI-statement">
                  <p>
                    <bold>Tim Illidge</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Takeda, Nordic Nanovector</p>
                  <p><bold>Speakers' Bureau:</bold> Takeda, Bristol Myers Squibb, Roche</p>
                  <p><bold>Research Funding:</bold> AstraZeneca/MedImmune, MSD Oncology</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Roche</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engert</surname><given-names>A</given-names></name><name><surname>Plütschow</surname><given-names>A</given-names></name><name><surname>Eich</surname><given-names>HT</given-names></name><etal>et al</etal></person-group><article-title>Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma</article-title><source>N Engl J Med</source><volume>363</volume><fpage>640</fpage>–<lpage>652</lpage><year>2010</year><pub-id pub-id-type="pmid">20818855</pub-id></mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleman</surname><given-names>BM</given-names></name><name><surname>van den Belt-Dusebout</surname><given-names>AW</given-names></name><name><surname>Klokman</surname><given-names>WJ</given-names></name><etal>et al</etal></person-group><article-title>Long-term cause-specific mortality of patients treated for Hodgkin's disease</article-title><source>J Clin Oncol</source><volume>21</volume><fpage>3431</fpage>–<lpage>3439</lpage><year>2003</year><pub-id pub-id-type="pmid">12885835</pub-id></mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>RM</given-names></name><name><surname>Gospodarowicz</surname><given-names>MK</given-names></name><name><surname>Connors</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma</article-title><source>N Engl J Med</source><volume>366</volume><fpage>399</fpage>–<lpage>408</lpage><year>2012</year><pub-id pub-id-type="pmid">22149921</pub-id></mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andre</surname><given-names>MPE</given-names></name><name><surname>Girinsky</surname><given-names>T</given-names></name><name><surname>Federico</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: Final results of the randomized EORTC/LYSA/FIL H10 trial</article-title><source>J Clin Oncol</source><volume>35</volume><fpage>1786</fpage>–<lpage>1794</lpage><year>2017</year><pub-id pub-id-type="pmid">28291393</pub-id></mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radford</surname><given-names>J</given-names></name><name><surname>Illidge</surname><given-names>T</given-names></name><name><surname>Counsell</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma</article-title><source>N Engl J Med</source><volume>372</volume><fpage>1598</fpage>–<lpage>1607</lpage><year>2015</year><pub-id pub-id-type="pmid">25901426</pub-id></mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname><given-names>M</given-names></name><name><surname>Goergen</surname><given-names>H</given-names></name><name><surname>Kobe</surname><given-names>C</given-names></name><etal>et al</etal></person-group><article-title>Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: Final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group</article-title><source>J Clin Oncol</source><volume>37</volume><fpage>2835</fpage>–<lpage>2845</lpage><year>2019</year><pub-id pub-id-type="pmid">31498753</pub-id></mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrington</surname><given-names>SF</given-names></name><name><surname>Mackewn</surname><given-names>JE</given-names></name><name><surname>Schleyer</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma</article-title><source>Ann Oncol</source><volume>22</volume><fpage>739</fpage>–<lpage>745</lpage><year>2011</year><pub-id pub-id-type="pmid">20813876</pub-id></mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>AK</given-names></name><name><surname>Bernardo</surname><given-names>MP</given-names></name><name><surname>Weller</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger</article-title><source>J Clin Oncol</source><volume>20</volume><fpage>2101</fpage>–<lpage>2108</lpage><year>2002</year><pub-id pub-id-type="pmid">11956271</pub-id></mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koh</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Tran</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Heydarian</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: Reduction in normal tissue dose and second cancer risk</article-title>
                  <source>Radiat Oncol</source>
                  <volume>2</volume>
                  <fpage>13</fpage>
                  <year>2007</year>
                  <pub-id pub-id-type="pmid">17362522</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maraldo</surname><given-names>MV</given-names></name><name><surname>Lundemann</surname><given-names>M</given-names></name><name><surname>Vogelius</surname><given-names>IR</given-names></name><etal>et al</etal></person-group><article-title>A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma</article-title><source>Radiother Oncol</source><volume>114</volume><fpage>206</fpage>–<lpage>211</lpage><year>2015</year><pub-id pub-id-type="pmid">25620063</pub-id></mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yahalom</surname><given-names>J</given-names></name><name><surname>Mauch</surname><given-names>P</given-names></name></person-group><article-title>The involved field is back: Issues in delineating the radiation field in Hodgkin's disease</article-title><source>Ann Oncol</source><volume>13</volume><issue>suppl 1</issue><fpage>79</fpage>–<lpage>83</lpage><year>2002</year><pub-id pub-id-type="pmid">12078908</pub-id></mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cutter</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Schaapveld</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Darby</surname>
                      <given-names>SC</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Risk of valvular heart disease after treatment for Hodgkin lymphoma</article-title>
                  <source>J Natl Cancer Inst</source>
                  <volume>107</volume>
                  <fpage>djv008</fpage>
                  <year>2015</year>
                  <pub-id pub-id-type="pmid">25713164</pub-id>
                </mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Nimwegen</surname><given-names>FA</given-names></name><name><surname>Schaapveld</surname><given-names>M</given-names></name><name><surname>Cutter</surname><given-names>DJ</given-names></name><etal>et al</etal></person-group><article-title>Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma</article-title><source>J Clin Oncol</source><volume>34</volume><fpage>235</fpage>–<lpage>243</lpage><year>2016</year><pub-id pub-id-type="pmid">26573075</pub-id></mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Nimwegen</surname><given-names>FA</given-names></name><name><surname>Ntentas</surname><given-names>G</given-names></name><name><surname>Darby</surname><given-names>SC</given-names></name><etal>et al</etal></person-group><article-title>Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines</article-title><source>Blood</source><volume>129</volume><fpage>2257</fpage>–<lpage>2265</lpage><year>2017</year><pub-id pub-id-type="pmid">28143884</pub-id></mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bruin</surname><given-names>ML</given-names></name><name><surname>Dorresteijn</surname><given-names>LD</given-names></name><name><surname>van't Veer</surname><given-names>MB</given-names></name><etal>et al</etal></person-group><article-title>Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma</article-title><source>J Natl Cancer Inst</source><volume>101</volume><fpage>928</fpage>–<lpage>937</lpage><year>2009</year><pub-id pub-id-type="pmid">19535773</pub-id></mixed-citation>
              </ref>
              <ref id="b16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>J</given-names></name><name><surname>Rapsomaniki</surname><given-names>E</given-names></name><name><surname>Pujades-Rodriguez</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>How does cardiovascular disease first present in women and men? Incidence of 12 cardiovascular diseases in a contemporary cohort of 1,937,360 people</article-title><source>Circulation</source><volume>132</volume><fpage>1320</fpage>–<lpage>1328</lpage><year>2015</year><pub-id pub-id-type="pmid">26330414</pub-id></mixed-citation>
              </ref>
              <ref id="b17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maraldo</surname><given-names>MV</given-names></name><name><surname>Brodin</surname><given-names>NP</given-names></name><name><surname>Vogelius</surname><given-names>IR</given-names></name><etal>et al</etal></person-group><article-title>Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>83</volume><fpage>1232</fpage>–<lpage>1237</lpage><year>2012</year><pub-id pub-id-type="pmid">22270170</pub-id></mixed-citation>
              </ref>
              <ref id="b18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppe</surname><given-names>BS</given-names></name><name><surname>Flampouri</surname><given-names>S</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><etal>et al</etal></person-group><article-title>Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>84</volume><fpage>449</fpage>–<lpage>455</lpage><year>2012</year><pub-id pub-id-type="pmid">22386373</pub-id></mixed-citation>
              </ref>
              <ref id="b19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>BA</given-names></name><name><surname>Hornby</surname><given-names>C</given-names></name><name><surname>Cunninghame</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Minimising critical organ irradiation in limited stage Hodgkin lymphoma: A dosimetric study of the benefit of involved node radiotherapy</article-title><source>Ann Oncol</source><volume>23</volume><fpage>1259</fpage>–<lpage>1266</lpage><year>2012</year><pub-id pub-id-type="pmid">21980193</pub-id></mixed-citation>
              </ref>
              <ref id="b20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koeck</surname><given-names>J</given-names></name><name><surname>Abo-Madyan</surname><given-names>Y</given-names></name><name><surname>Lohr</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin study group (GHSG): The roles of intensity-modulated radiotherapy and involved-node radiotherapy</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>83</volume><fpage>268</fpage>–<lpage>276</lpage><year>2012</year><pub-id pub-id-type="pmid">22079733</pub-id></mixed-citation>
              </ref>
              <ref id="b21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plowman</surname><given-names>PN</given-names></name></person-group><article-title>Radiotherapy considerations in patients with Hodgkin's disease who receive mediastinal radiotherapy and anthracycline-containing chemotherapy</article-title><source>Clin Oncol (R Coll Radiol)</source><volume>10</volume><fpage>384</fpage>–<lpage>391</lpage><year>1998</year><pub-id pub-id-type="pmid">9890541</pub-id></mixed-citation>
              </ref>
              <ref id="b22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntentas</surname><given-names>G</given-names></name><name><surname>Dedeckova</surname><given-names>K</given-names></name><name><surname>Andrlik</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Clinical intensity modulated proton therapy for Hodgkin lymphoma: Which patients benefit the most?</article-title><source>Pract Radiat Oncol</source><volume>9</volume><fpage>179</fpage>–<lpage>187</lpage><year>2019</year><pub-id pub-id-type="pmid">30708133</pub-id></mixed-citation>
              </ref>
              <ref id="b23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Nimwegen</surname><given-names>FA</given-names></name><name><surname>Schaapveld</surname><given-names>M</given-names></name><name><surname>Janus</surname><given-names>CP</given-names></name><etal>et al</etal></person-group><article-title>Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk</article-title><source>JAMA Intern Med</source><volume>175</volume><fpage>1007</fpage>–<lpage>1017</lpage><year>2015</year><pub-id pub-id-type="pmid">25915855</pub-id></mixed-citation>
              </ref>
              <ref id="b24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aleman</surname><given-names>BM</given-names></name><name><surname>van den Belt-Dusebout</surname><given-names>AW</given-names></name><name><surname>De Bruin</surname><given-names>ML</given-names></name><etal>et al</etal></person-group><article-title>Late cardiotoxicity after treatment for Hodgkin lymphoma</article-title><source>Blood</source><volume>109</volume><fpage>1878</fpage>–<lpage>1886</lpage><year>2007</year><pub-id pub-id-type="pmid">17119114</pub-id></mixed-citation>
              </ref>
              <ref id="b25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myrehaug</surname><given-names>S</given-names></name><name><surname>Pintilie</surname><given-names>M</given-names></name><name><surname>Tsang</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy</article-title><source>Leuk Lymphoma</source><volume>49</volume><fpage>1486</fpage>–<lpage>1493</lpage><year>2008</year><pub-id pub-id-type="pmid">18608873</pub-id></mixed-citation>
              </ref>
              <ref id="b26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pihkala</surname><given-names>J</given-names></name><name><surname>Saarinen</surname><given-names>UM</given-names></name><name><surname>Lundström</surname><given-names>U</given-names></name><etal>et al</etal></person-group><article-title>Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation</article-title><source>Eur J Cancer</source><volume>32A</volume><fpage>97</fpage>–<lpage>103</lpage><year>1996</year><pub-id pub-id-type="pmid">8695252</pub-id></mixed-citation>
              </ref>
              <ref id="b27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swerdlow</surname><given-names>AJ</given-names></name><name><surname>Higgins</surname><given-names>CD</given-names></name><name><surname>Smith</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Myocardial infarction mortality risk after treatment for Hodgkin disease: A Collaborative British Cohort Study</article-title><source>J Natl Cancer Inst</source><volume>99</volume><fpage>206</fpage>–<lpage>214</lpage><year>2007</year><pub-id pub-id-type="pmid">17284715</pub-id></mixed-citation>
              </ref>
              <ref id="b28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ntentas</surname><given-names>G</given-names></name><name><surname>Darby</surname><given-names>SC</given-names></name><name><surname>Aznar</surname><given-names>MC</given-names></name><etal>et al</etal></person-group><article-title>Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction</article-title><source>Radiother Oncol</source><volume>153</volume><fpage>155</fpage>–<lpage>162</lpage><year>2020</year><pub-id pub-id-type="pmid">32890611</pub-id></mixed-citation>
              </ref>
              <ref id="b29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vordermark</surname><given-names>D</given-names></name><name><surname>Seufert</surname><given-names>I</given-names></name><name><surname>Schwab</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Cardiac toxicity of mediastinal radiotherapy: Which are the critical structures?</article-title><source>J Clin Oncol</source><volume>23</volume><fpage>3634</fpage>–<lpage>3636</lpage><year>2005</year><comment>author reply 3636</comment><pub-id pub-id-type="pmid">15908679</pub-id></mixed-citation>
              </ref>
              <ref id="b30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoppe</surname><given-names>BS</given-names></name><name><surname>Bates</surname><given-names>JE</given-names></name><name><surname>Mendenhall</surname><given-names>NP</given-names></name><etal>et al</etal></person-group><article-title>The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era</article-title><source>Pract Radiat Oncol</source><volume>10</volume><fpage>e147</fpage>–<lpage>e154</lpage><year>2020</year><pub-id pub-id-type="pmid">31586483</pub-id></mixed-citation>
              </ref>
              <ref id="b31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Illidge</surname><given-names>TM</given-names></name><name><surname>Phillips</surname><given-names>EH</given-names></name><name><surname>Counsell</surname><given-names>N</given-names></name><etal>et al</etal></person-group><article-title>Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma</article-title><source>Blood Adv</source><volume>4</volume><fpage>203</fpage>–<lpage>206</lpage><year>2020</year><pub-id pub-id-type="pmid">31935289</pub-id></mixed-citation>
              </ref>
              <ref id="b32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Specht</surname><given-names>L</given-names></name><name><surname>Yahalom</surname><given-names>J</given-names></name><name><surname>Illidge</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>89</volume><fpage>854</fpage>–<lpage>862</lpage><year>2014</year><pub-id pub-id-type="pmid">23790512</pub-id></mixed-citation>
              </ref>
              <ref id="b33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paumier</surname><given-names>A</given-names></name><name><surname>Ghalibafian</surname><given-names>M</given-names></name><name><surname>Gilmore</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma</article-title><source>Int J Radiat Oncol Biol Phys</source><volume>82</volume><fpage>1522</fpage>–<lpage>1527</lpage><year>2012</year><pub-id pub-id-type="pmid">21705151</pub-id></mixed-citation>
              </ref>
              <ref id="b34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starke</surname><given-names>A</given-names></name><name><surname>Bowden</surname><given-names>J</given-names></name><name><surname>Lynn</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma</article-title><source>Radiother Oncol</source><volume>129</volume><fpage>449</fpage>–<lpage>455</lpage><year>2018</year><pub-id pub-id-type="pmid">30245037</pub-id></mixed-citation>
              </ref>
              <ref id="b35">
                <label>35.</label>
                <mixed-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pinnix</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Gunther</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Fang</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal>et al</etal>
                  </person-group>
                  <article-title>Assessment of radiation doses delivered to organs at risk among patients with early-stage favorable Hodgkin lymphoma treated with contemporary radiation therapy</article-title>
                  <source>JAMA Netw Open</source>
                  <volume>3</volume>
                  <fpage>e2013935</fpage>
                  <year>2020</year>
                  <pub-id pub-id-type="pmid">32990738</pub-id>
                </mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
